林业发展局核准CT-132,这是预防成人偏头痛的一种新的数字应用程序治疗方法。 FDA approves CT-132, a new digital app treatment for preventing migraines in adults.

林业发展局批准了CT-132,这是预防成人偏头痛的第一个处方数字治疗方案。 The FDA has approved CT-132, the first prescription digital therapeutic for preventing migraines in adults. CT-132通过移动应用程序交付,旨在通过为期12周的方案降低大脑对触发器的敏感性。 Delivered via a mobile app, CT-132 aims to reduce brain sensitivity to triggers through a 12-week program. 临床试验显示,在使用标准药物的同时,它大大减少了偏头痛日,并提高了生活质量。 Clinical trials showed it significantly reduced migraine days and improved quality of life when used alongside standard medications. 没有报告严重的副作用。 No serious side effects were reported.